The study encompassed 13 pediatric transplant centers across the United States and Canada, reviewing over 3,000 liver transplant recipients’ electronic health data. From this vast dataset, 148 adolescents and young adults were identified as high-risk for organ rejection based on their MLVI scores. Participants were then randomized to receive either standard post-transplant care or a two-year, telehealth-based behavioral intervention aimed at improving medication adherence. This remote intervention involved regular check-ins and support from trained specialists, providing a scalable and patient-centered approach to healthcare delivery.

While the primary endpoint—a composite measure assessing rejection incidents, need for retransplantation, and withdrawal of consent—did not reach statistical significance, this outcome was largely due to unexpectedly low rejection rates in both treatment groups. Notably, the group receiving behavioral intervention exhibited roughly half the number of rejection-related events compared to those under standard care. These findings underscore the potential clinical benefit of combining MLVI-guided risk stratification with proactive remote intervention to reduce organ rejection, minimizing severe complications before they arise.

Traditionally, transplant clinicians have struggled to objectively identify patients who inconsistently take their immunosuppressant medications, due to the reliance on self-reported adherence or expensive and laborious monitoring methods. MLVI innovates on these fronts by using intra-patient variability in drug blood concentrations—collected routinely during follow-up laboratory assessments—as an objective, quantifiable metric. Because transplant recipients undergo frequent therapeutic drug monitoring, MLVI harnesses existing clinical data streams, facilitating risk assessment without additional burden or cost.

Eyal Shemesh, MD, Chief of Behavioral and Developmental Health at Mount Sinai Kravis Children’s Hospital and lead investigator of the study, highlighted the profound shift this technology enables: “Our findings show that we can detect early nonadherence by using data already embedded in electronic health records, allowing clinicians to intervene proactively, a strategy years ahead of reactive treatment post-rejection.” Dr. Shemesh’s dual expertise in pediatrics and psychiatry informs a nuanced understanding of adolescent health behaviors in the transplant context, emphasizing the study’s translational potential.

Adolescents and young adults represent a particularly vulnerable demographic in transplant care due to developmental, psychological, and social challenges that affect consistent medication use. The MLVI marker and subsequent remote intervention address these challenges by tailoring care management to individual risk profiles. This precision medicine approach not only improves outcomes but could also alleviate healthcare system burdens by reducing hospitalizations and retransplant rates, thereby preserving scarce donor organs and enhancing quality of life for recipients.

An integral component of the study’s success was its innovative telehealth platform, which maintained continuous engagement with patients through the COVID-19 pandemic, a period that intensified healthcare access disparities. Through virtual check-ins, behavioral coaching, and personalized support, the intervention demonstrated that even high-risk patients could achieve sustained adherence. This model suggests new avenues for scalable, resource-efficient care delivery, adaptable to broad clinical settings beyond transplantation.

Benjamin L. Shneider, MD, senior author and Chief of Gastroenterology at Texas Children’s Hospital, emphasized the practical implications: “This study paves the way for early detection and intervention for nonadherence before life-threatening rejection occurs. The use of MLVI combined with remote behavioral support offers a blueprint to optimize pediatric liver transplant outcomes and may revolutionize chronic disease management for children and families worldwide.”

George Mazariegos, MD, Chair of the Starzl Network for Excellence in Pediatric Transplantation, reinforced the broader impact, noting that early behavioral correction informed by objective risk markers could reshape lifelong care strategies for transplant recipients. His position at a leading pediatric transplant center amplifies the significance of incorporating MLVI into clinical workflows to systematically improve patient trajectories.

Despite the encouraging clinical trends, researchers acknowledge that the intervention’s efficacy, efficiency, and cost-effectiveness require further rigorous evaluation. Nonetheless, the study provides compelling evidence supporting the integration of MLVI into routine post-transplant care protocols, moving clinical practice toward preemptive, data-driven management rather than reliance on reactive measures after complications arise.

This novel application of electronic health record data analytics marks a critical advance in personalized transplant medicine. By capturing medication adherence patterns objectively and remotely intervening to support behavioral change, healthcare teams can stabilize graft function, reduce morbidity, and extend graft survival. The convergence of routine lab data, telehealth innovation, and behavioral science exemplifies the future of precision medicine in complex chronic conditions.

Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, this research underscores the power of collaborative, multicenter efforts to tackle persistent challenges in transplant medicine. As healthcare systems increasingly digitize, leveraging EHR-derived metrics like MLVI for proactive patient management may extend well beyond transplantation to improve outcomes across numerous chronic illnesses.

In conclusion, this study establishes MLVI as a transformative, objective risk stratification tool and confirms the feasibility and promise of remote behavioral interventions in improving medication adherence among adolescent transplant patients. This paradigm shift from reaction to prevention has the potential to revolutionize transplant care and pave the way for broader applications in chronic disease management, illustrating the profound impact of integrating electronic health records with innovative clinical strategies.

Subject of Research:
Medication nonadherence and risk stratification in adolescent liver transplant recipients using an EHR-derived marker to predict and prevent organ rejection.

Article Title:
A remote intervention to improve medication nonadherence guided by a marker of risk derived from the electronic health records of adolescent transplant recipients.

News Publication Date:
June 15, 2026

Web References:
https://www.mountsinai.org
https://www.texaschildrens.org
https://doi.org/10.1016/j.ajt.2026.04.03

References:
American Journal of Transplantation, Article DOI: 10.1016/j.ajt.2026.04.03, Published May 27, 2026

Keywords:
Transplantation, Medication adherence, Electronic health records, Adolescents, Liver transplantation, Immunosuppressant variability, Remote behavioral intervention, Telehealth, Chronic disease management, Organ rejection prevention, Pediatric transplant care, Precision medicine

The study, conducted by researchers from Baylor College of Medicine, Houston, meticulously analyzed an unprecedented span of nearly four decades, reviewing approximately 1.5 million adult listings in the United Network for Organ Sharing database. This extensive dataset allowed the researchers to probe deeply into the dynamics of unmet need, intent-to-treat survival, and post-transplant survival, offering invaluable insights into the complexities of the organ transplantation ecosystem.

Intent-to-treat survival, defined as the proportion of patients alive one year after being listed for an organ regardless of receiving a transplant, unveiled impressive improvements. Lung transplant recipients showcased the most dramatic enhancement, with survival increasing from 38% to an extraordinary 84%. Similar upward trajectories were observed among heart, liver, kidney, and pancreas transplant candidates, reflecting the integrated impact of systemic medical advancements.

One-year post-transplant survival, a critical metric representing survival rates after surgery, also witnessed marked improvements across all organ types. Notably, kidney transplant patients who received organs from living donors consistently demonstrated superior survival compared to those receiving deceased donor transplants, emphasizing the profound impact of donor source on clinical outcomes and shaping future transplant strategies.

However, the study highlights a paradox: while survival rates improve, the unmet need—measured as the discrepancy between the number of waitlisted patients and transplants performed annually—remains significant. Encouragingly, a decline in this gap is evident in liver, heart, pancreas, and lung transplants, with unmet needs shrinking by as much as 80% in lung cases from the late 1990s to 2023, signaling progress in organ availability and allocation efficacy.

The kidney transplantation landscape presents a stark contrast. Demand for kidney transplants has surged by approximately 350 to 400% over the past thirty years. From roughly 4,000 patients with unmet need in 1988, numbers soared to nearly 18,500 by 2023. This persistent—and in fact growing—unmet need highlights the critical bottleneck in supply, reflecting the unique challenges in kidney donation and reinforcing the organ’s paramount demand.

Survival improvements are rooted in multifaceted advancements spanning anesthesia, perioperative care, infectious disease management, and critical care protocols. These medical progressions have radically reshaped patient trajectories, enabling longer survival on organ waiting lists and enhancing postoperative recovery. Enhanced organ preservation techniques and broader donor criteria have further extended the reach of transplantation, though their benefits have varied among different organ groups.

Emerging technologies, such as xenotransplantation, hold promise but remain in nascent stages, with limited clinical trials offering preliminary evidence rather than widespread clinical adoption. The potential of xenotransplantation to alleviate donor shortages is tantalizing, yet its current developmental status restricts its immediate impact on the transplantation supply-demand imbalance.

The psychological and clinical journey of transplant candidates commences well before the operating room door opens. Intent-to-treat analyses underscore survival trends from listing through transplantation, emphasizing that improvements in care must encompass pre-transplant stages, including medical optimization and waiting list management, to holistically improve outcomes.

Despite the encouraging survival figures, the study underscores the indispensability of increasing organ donation rates to sustain and accelerate progress. “Organ transplant patients are living longer both before and after surgery thanks to several clinical and technical innovations,” said Dr. Abbas Rana, senior author and professor of surgery at Baylor College of Medicine. Yet, the undeniable mismatch between organ availability and need limits the full realization of these medical achievements.

Limitations of the study arise from the inherent constraints of the UNOS database, which may not fully account for regional disparities, proximity to transplant centers, or nuanced socioeconomic variables known to influence transplant access and outcomes. Additionally, evolving transplant eligibility criteria and variable donor and recipient risk profiles over time were not accounted for, potentially impacting trend interpretations.

Policy and clinical innovations emphasizing better organ preservation and optimized utilization have successfully enhanced transplant numbers. In 2025, a record 49,064 transplants were performed in the United States, reflecting these shifts. However, the increase in transplant volume must be paralleled by donor pool expansion to prevent stalling progress.

This longitudinal research shines a revealing light on the complex interplay of medical advancements and systemic challenges within organ transplantation. It delineates a future where cutting-edge technologies, comprehensive patient care, and intensified donation campaigns converge to mitigate the burden of organ failure, ultimately striving toward a world where the waiting list is no longer a barrier to survival.

As medical science traverses new frontiers, the transplant community remains vigilant, acknowledging that the true measure of success lies not only in surgical and perioperative excellence but also in addressing the systemic gap in organ availability—which remains the defining challenge of modern transplantation medicine.

Subject of Research: People
Article Title: Trends in Survival and Unmet Need Across Solid-Organ Transplantation
News Publication Date: 2-Apr-2026
Web References: https://dx.doi.org/10.1097/XCS.0000000000001852
References: Burns C, Sangineni P, Myres S, et al. Trends in Survival and Unmet Need Across Solid-Organ Transplantation. Journal of the American College of Surgeons, 2026. DOI: 10.1097/XCS.0000000000001852
Keywords: Organ donation, Transplantation, Survival rates, Kidney transplantation, Solid-organ transplant, Medical advancements, Organ preservation, Xenotransplantation

The process of organ donation after circulatory death involves a unique and intricate scenario where donors are declared dead following the cessation of cardiac function. Traditionally, organs from these donors were viewed as less desirable due to concerns over viability and function post-transplant. However, recent studies demonstrated that, with the right protocols and advancements in preservation techniques, these organs can be utilized effectively, offering hope to countless patients who are battling liver disease. This research is critical at a time when the gap between organ demand and supply continues to widen alarmingly.

One of the primary challenges faced in utilizing liver grafts from DCD donors is the understanding of the mechanisms that contribute to post-transplant graft function. Croome’s research meticulously analyzes various factors that can influence liver graft viability, including ischemia-reperfusion injury, a condition that affects the organ’s function following the period of inadequate blood supply. Understanding this injury provides essential insights into how surgeons and medical teams can mitigate its effects, thereby enhancing liver graft survival rates.

Central to Croome’s findings is the development of standardized protocols for the retrieval and preservation of DCD livers. The study underscores that employing advanced machine perfusion systems can significantly improve outcomes by ensuring that the liver graft remains in optimal condition during the critical waiting period. This active preservation method not only enhances the metabolic parameters of the graft but also reduces the detrimental effects associated with cold storage, which has been the traditional approach.

Moreover, the research indicates that tailored donor selection criteria play an indispensable role in optimizing graft utilization. By employing robust pre-donation assessments, including thorough medical history evaluations and careful consideration of the circumstances surrounding the donor’s death, clinicians can identify the most suitable candidates for liver donation. This precision in selection directly corresponds to improved graft outcomes and patient survival rates, marking a significant leap forward in transplant practices.

The implications of these findings extend beyond just the technical aspects of organ preservation and selection. Croome emphasizes the ethical considerations surrounding DCD donation. As the medical community navigates this complex landscape, it is crucial to balance the urgency of addressing the organ shortage with the moral obligations to respect donor families and honor their wishes. Ensuring that families are fully informed and supported throughout the donation process stands at the forefront of this ethical consideration.

In light of these advancements, the integration of novel technologies into the transplantation protocol also merits attention. Innovations such as precision medicine, which tailors medical treatment to the individual characteristics of each patient, further improve outcomes in liver transplantation. By utilizing genetic and biomarker assessments, healthcare professionals can predict how well a graft will perform in different patients, potentially reducing the rates of rejection and other complications post-surgery.

Another critical area examined in Croome’s study is the collaboration between transplant centers and regulatory bodies. Establishing a robust framework for monitoring and evaluating DCD programs ensures that best practices are consistently followed. This collaborative effort can foster an environment of continuous improvement and innovation, ultimately leading to greater efficacy in the utilization of livers from DCD donors.

As the field continues to innovate, ongoing education and training programs for transplant surgeons and medical personnel become essential. A thorough understanding of the unique challenges and potential solutions associated with DCD organ transplantation is necessary to equip these professionals for success. By investing in the education of healthcare teams, the medical community can cultivate a culture of excellence in organ transplantation.

Chronicling the journey of DCD organ transplantation reveals an exciting frontier that blends science, ethics, and patient care. The research led by K.P. Croome not only enhances our comprehension of liver graft utilization but also serves as a beacon of hope for patients in dire need of transplants. The evidence presented in this study may potentially guide future global initiatives aimed at maximizing the use of available organs and motivating societies to embrace the concept of organ donation more fluidly.

Furthermore, as we push the boundaries of what is possible in organ transplantation, it is vital to engage in discussions that include patients and their families in the decision-making process. Their experiences and insights can provide invaluable perspectives that might refine our approach to organ donation and utilization. Advocacy and education programs will play a crucial role in raising awareness and encouraging conversations around this essential issue.

By fostering a culture of openness regarding organ donation and transplantation, society can begin to dismantle the barriers that have historically restrained the acceptance and understanding of this life-saving practice. The findings in Croome’s research not only elevate our understanding of the technical aspects of liver transplantation but also emphasize the human experience that lies at the heart of these complex procedures.

Ultimately, the advancements encapsulated in this research offer a roadmap for the optimal utilization of liver grafts from DCD donors, providing hope and renewed life to patients who might previously have been overlooked. As we move forward, the medical community must take these findings to heart, implementing them with an unwavering commitment to enhancing the state of organ transplantation. The optimization of liver grafts from DCD donors is not merely a technical enhancement; it is a step towards redefining how we approach the gift of life itself.

In this remarkable journey of advancing transplantation practices, the work of researchers like K.P. Croome serves as a crucial catalyst for change. The future of organ transplantation hinges on our ability to innovate, educate, and ultimately, to empathize with those affected by the dire need for organ donation. Through collaboration and dedication to excellence, we can reshape the narrative surrounding liver transplantation and save countless lives in the process.

Subject of Research: Optimization of Liver Graft Utilization from Donation after Circulatory Death Donors

Article Title: Optimization of Liver Graft Utilization from Donation after Circulatory Death Donors

Article References:

Croome, K.P. Optimization of Liver Graft Utilization from Donation after Circulatory Death Donors.
Curr Transpl Rep 12, 7 (2025). https://doi.org/10.1007/s40472-025-00465-9

Image Credits: AI Generated

DOI: 10.1007/s40472-025-00465-9

Keywords: liver graft, donation after circulatory death, organ transplantation, ischemia-reperfusion injury, donor selection, machine perfusion, transplant protocols, ethical considerations, precision medicine, collaboration, education, organ donation awareness.

Tacrolimus, a cornerstone immunosuppressant used to prevent organ rejection, presents a narrow therapeutic index, with significant variability in pharmacokinetics and pharmacodynamics among individuals. This variability often necessitates meticulous and frequent dose adjustments to mitigate risks such as graft rejection or drug toxicity. Traditional dosing protocols rely heavily on population-based averages, which may inadequately account for patient-specific factors influencing drug metabolism and response.

The study spearheaded by Khong, Lee, Warren, and collaborators addresses this critical gap by employing phenotypic markers to tailor tacrolimus dosing. Phenotypic personalized medicine here refers to assessing measurable biological characteristics—such as enzyme activity levels, drug metabolite profiles, and immunological parameters—that offer real-time insight into an individual patient’s drug disposition and immune status. Incorporating these phenotypes facilitates a more precise dosing strategy that transcends the current “one-size-fits-most” paradigm.

In this rigorous randomized controlled trial, liver transplant recipients were assigned to either standard dosing protocols or a phenotypic-guided dosing arm. The phenotypic approach integrated biomarker assessments, including cytochrome P450 3A5 (CYP3A5) enzyme genotyping and metabolic activity assays, alongside immune function assays, to dynamically modulate tacrolimus doses. This methodology harnesses advances in molecular diagnostics and immunology to personalize therapy in a clinically meaningful manner.

One of the pivotal findings of this phase 2 trial was the enhanced stability of tacrolimus blood concentrations among patients receiving phenotypic-guided dosing. This stability is clinically significant because it reduces the incidence of subtherapeutic exposure that predisposes patients to rejection episodes as well as supratherapeutic levels that contribute to nephrotoxicity and other adverse events. The phenotypic approach demonstrated a notable reduction in dose adjustments and outpatient visits for therapeutic drug monitoring, underscoring its potential to improve healthcare efficiency.

Moreover, the trial revealed that phenotypic dosing correlated with a lower incidence of acute rejection during the critical early post-transplant period, hinting at improved immunological control through optimized drug exposure. This is remarkable given how early graft rejection substantially affects long-term transplant success and patient survival. By finely tuning immunosuppression, phenotypic-guided protocols may strike a better immunological balance, preserving graft function without overtreatment.

This study’s strength lies in its multidisciplinary integration of pharmacogenomics, pharmacokinetics, and immunophenotyping, highlighting the convergence of these fields to tailor therapy on an individual basis. Importantly, the researchers utilized advanced bioanalytical techniques to capture dynamic phenotypic data, which required sophisticated laboratory infrastructure and clinical expertise. These developments mark a significant step toward precision medicine in transplantation, a field that has long lagged behind oncology and other areas in personalized approaches.

The implications extend beyond liver transplantation. Tacrolimus remains a mainstay for kidney, heart, and lung transplants, where similar pharmacologic challenges persist. If phenotypic personalized dosing proves robust across organ types and larger cohorts, it could herald a new era of immunosuppressive management, potentially decreasing morbidity, improving graft longevity, and reducing healthcare costs.

The study also underscores the evolving role of machine learning and computational modeling in transplant pharmacology. The integration of phenotypic data can feed into predictive algorithms that anticipate an individual’s response to tacrolimus, adapting doses preemptively rather than reactively. This proactive dosing paradigm could revolutionize clinical workflows, transforming tacrolimus management into a dynamic, data-informed practice rather than a static protocol-driven one.

However, certain challenges remain before widespread clinical adoption. The need for specialized assays and the cost of phenotyping may limit immediate accessibility, particularly in resource-constrained settings. Additionally, the complexity of transplant immunology means phenotypic personalization may never be fully predictive; hence, clinical judgment remains indispensable. Long-term studies are necessary to validate the durability of benefits concerning graft survival and patient quality of life.

Furthermore, this trial paves the way for exploring additional biomarkers that could refine immunosuppressive regimens. Beyond CYP3A5 and metabolite monitoring, inflammatory cytokines, immune cell subset profiling, and even microbiome interactions might emerge as influential factors governing tacrolimus response. Such multidimensional phenotyping could further enhance individualized therapy, aligning with the larger precision medicine movement sweeping through healthcare.

Another fascinating aspect is the psychosocial and patient engagement angle. Personalized dosing strategies inherently require close communication between patients and clinicians, fostering collaborative care models. Patients empowered with knowledge about their unique drug response characteristics may exhibit improved adherence and satisfaction, factors which are crucial for the success of long-term therapies vital in transplantation.

This investigation into phenotypic dosing also challenges the regulatory and logistical frameworks governing transplant pharmacotherapy. Integrating innovative diagnostic tools into clinical practice demands updates to guidelines, reimbursement policies, and practitioner education. Stakeholders including transplant centers, laboratories, and policymakers must collaborate to create environments conducive to adopting personalized immunosuppression strategies.

In summary, Khong and colleagues’ landmark phase 2 clinical trial introduces a compelling vision for tacrolimus dosing in liver transplant recipients by harnessing phenotypic personalized medicine. Their work elucidates the potential for improved drug exposure stability, reduced rejection risk, and enhanced patient care through individualized therapeutic regimens grounded in deep biological insight. This approach embodies the future of transplantation, where precision and personalization are not aspirational but integral components of clinical practice, offering hope for enhanced transplant success in the years ahead.

Subject of Research: Tacrolimus dosing optimization in liver transplant recipients using phenotypic personalized medicine.

Article Title: Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial.

Article References:
Khong, J., Lee, M., Warren, C. et al. Tacrolimus dosing in liver transplant recipients using phenotypic personalized medicine: A phase 2 randomized clinical trial. Nat Commun 16, 4558 (2025). https://doi.org/10.1038/s41467-025-59739-6

Image Credits: AI Generated